Funded Startups in Norcross
Across the 7 most recent funded startups listed for Norcross, the largest disclosed round is McLarens’ $1.6B (2025-10-16), which dwarfs the next-largest di…
Across the 7 most recent funded startups listed for Norcross, the largest disclosed round is McLarens’ $1.6B (2025-10-16), which dwarfs the next-largest disclosed amounts: Galectin Therapeutics at $10M (2025-07-09) and Renew Digital at $11M (2023-10-25). In contrast, the disclosed rounds mostly cluster in the low single-digit millions or near $10–$11M (e.g., WEAV3D $3M on 2025-05-27; Sanguina $3M on 2023-07-25).
Date-wise, activity spans 2022-09-16 through 2025-10-16, with 4 of the 7 entries closing in 2025 (2025-05-22 to 2025-10-16). The list also shows a stage/amount disclosure mix: 2 of 7 rows are “undisclosed” (Koning on 2025-05-22; Stratix Corporation on 2022-09-16), and 5 of 7 rows carry “Series Unknown” versus named stages including Series C (Koning) and Series A (Sanguina). Sector coverage is broader, without a single sector appearing 3+ times.
Most recent rounds
7 shownRelated listings
Frequently asked
What’s the largest disclosed round in Norcross here, and is it an outlier versus the rest?
McLarens’ $1.6B (2025-10-16) is the only disclosed amount in the hundreds-of-millions+ range, and it dwarfs the next-largest disclosed rounds: Renew Digital at $11M (2023-10-25) and Galectin Therapeutics at $10M (2025-07-09). Most other disclosed amounts are $3M (WEAV3D on 2025-05-27; Sanguina on 2023-07-25) or $11M/$10M.
Do these Norcross entries cluster tightly by time in the most recent period?
Yes. 4 of 7 entries are dated in 2025, spanning from 2025-05-22 (Koning) through 2025-10-16 (McLarens). Within that 2025 window, three rounds fall between 2025-05-27 and 2025-07-09 (WEAV3D $3M on 2025-05-27; Koning undisclosed on 2025-05-22; Galectin Therapeutics $10M on 2025-07-09).
How often are rounds disclosed at all, based on “Series Unknown” and “undisclosed” amounts?
Disclosure is split: 5 of 7 rows list “Series Unknown” (McLarens, Galectin Therapeutics, WEAV3D, Renew Digital, and Sanguina), while 2 of 7 have “undisclosed” round amounts (Koning on 2025-05-22; Stratix Corporation on 2022-09-16). Among the disclosed-amount rows, the lowest disclosed amount is $3M (WEAV3D on 2025-05-27; Sanguina on 2023-07-25).
Is there a dominant stage pattern across this Norcross sample?
Named stages are the minority. Only Koning shows Series C (2025-05-22, undisclosed amount) and Sanguina shows Series A ($3M on 2023-07-25), while the remaining 5 entries are labeled “Series Unknown,” including Private Equity labels for McLarens ($1.6B on 2025-10-16) and Stratix Corporation (undisclosed amount on 2022-09-16).
Which sectors appear most, and are any sectors over-represented in this 7-company list?
No sector repeats enough to be clearly over-represented: each sector shown appears only once across the 7 rows (e.g., Biotechnology: Galectin Therapeutics; Manufacturing: WEAV3D; Data and Analytics: Koning; Hardware: Renew Digital; Apps: Sanguina; Consumer Electronics: Stratix Corporation; Insurance/Finance/Professional Services is specific to McLarens). The only cross-cutting pattern is that “Series Unknown” occurs in 5 of 7 entries, not a single repeated sector.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.